Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CC-97540 by Bristol-Myers Squibb for Marginal Zone B-cell Lymphoma: Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...
CC-97540 by Bristol-Myers Squibb for Systemic Lupus Erythematosus: Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
CC-97540 by Bristol-Myers Squibb for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsing Multiple Sclerosis (RMS). According to...
CC-97540 by Bristol-Myers Squibb for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS). According...
CC-97540 by Bristol-Myers Squibb for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Secondary Progressive Multiple Sclerosis (SPMS). According...
CC-97540 by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
CC-97540 by Bristol-Myers Squibb for Follicular Lymphoma: Likelihood of Approval
CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...